Drug Name: Ojjaara
Active Ingredient: momelotinib
Indications: To treat intermediate or high-risk myelofibrosis in adults with anemia
Approval Date: 9/15/2023
Company: GlaxoSmithKline
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf